Japan’s Chugai soars nearly 6% after UK says its drug reduces hospital time for Covid patients

SINGAPORE — Shares of Japanese drugmaker Chugai Pharmaceutical surged on Tuesday after the U.K. government found that its drug tocilizumab was effective in reducing risk of death as well as hospitalization time for Covid patients.

By the Tuesday market close in Japan, shares of Chugai rose 5.91%. Earlier in the session, Chugai’s stock soared as much as 16.26%. Tuesday marked the first trading day of the week for Chugai as Japan’s markets were closed on Monday for a holiday.

In a press release dated Thursday, the U.K. said results from a government-funded clinical trial showed tocilizumab was among two drugs that “reduced the relative risk of death by 24% when administered to patients within 24 hours of entering intensive care.”

The release also said that patients receiving the drugs, typically used to treat rheumatoid arthritis, “left intensive care between 7 to 10 days earlier on average.”

U.K. Health and Social Care Secretary Matt Hancock said the results marked “another landmark development in finding a way out of this pandemic.”

The government also said it will begin to encourage the use of tocilizumab for patients admitted to the ICU. NHS will also work with manufacturer Roche to ensure the treatment remains available for U.K. patients.

Tocilizumab, marketed as Actemra or RoActemra, is part of a co-development between Roche and Chugai. Roche is also the majority shareholder of Chugai.

Last week, Prime Minister Boris Johnson imposed a lockdown on England in a bid to contain a variant of Covid-19 that is more contagious than previous strains.

Coronavirus infection rates continue to surge in many parts of the world, even as countries begin vaccination rollouts. As a result, some governments have reintroduced social distancing restrictions.

To date, the disease has infected at least 90.8 million people and taken more than 1.9 million lives worldwide, according to data compiled by Johns Hopkins University.